A Study of Contrast-enhanced EBUS in Lung Lesions and Intrathoracic Lymph Nodes

Launched by SHANGHAI CHEST HOSPITAL · Jul 10, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to improve the diagnosis of lung problems, such as lung lesions (abnormal areas in the lung) and enlarged lymph nodes inside the chest. The study uses a special ultrasound technique called contrast-enhanced endobronchial ultrasound (CE-EBUS), which adds a safe contrast agent to help doctors see these areas more clearly. The goal is to find out if this method can help doctors better identify and understand these lung issues.

Adults over 18 who have certain lung abnormalities seen on scans, like enlarged lymph nodes or lung lesions near the airways, may be eligible to join. Participants need to be healthy enough to have a bronchoscopy—a procedure where a thin tube with a camera is passed into the lungs—and agree to the contrast-enhanced ultrasound during this test. People with serious heart or lung problems, allergies to the contrast agent, or who are pregnant cannot take part. If you join, you’ll undergo the CE-EBUS during your regular diagnostic procedure, which may help doctors get more accurate information about your lung condition. This study is currently recruiting patients and aims to improve how lung diseases are diagnosed in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \>18 years old；
• • Enlargement of at least one intrathoracic LN (short diameter \> 1 cm) or central parenchymal lung lesions adjacent to the airway detected on chest CT, or increased fluorodeoxyglucose uptake in at least one intrathoracic lymph node on PET / CT (standardized uptake value \> 2.5)；
• • CP-EBUS-TBNA is required to determine the diagnosis or staging, the patient agreed to undergo CE-EBUS, and there were no contraindications to EBUS-TBNA;
• • Patients who have good compliance and sign informed consent.
• Exclusion Criteria:
• • Patients with known hypersensitivity to ultrasound contrast components;
• • Patients with severe pulmonary hypertension (pulmonary artery pressure \> 90 mmHg);
• • Patients with angina pectoris, acute coronary syndrome, clinically unstable ischemic heart disease, heart failure, cardiac dysfunction, and cardiac disease with right-to-left shunting;
• • Patients with uncontrolled essential hypertension and adults with respiratory distress syndrome;
• • Pregnant or lactating women；
• • Patients with contraindications to bronchoscopy；
• • Patients with other conditions that, in the opinion of the investigator, make the patient unsuitable for the study.